RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

Multi-kinase RET inhibitors, such as cabozantinib and RXDX-105, are active in lung cancer patients with RET fusions; however, the overall response rates to these two drugs are unsatisfactory compared to other targeted therapy paradigms. Moreover, these inhibitors may have different efficacies agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Takuo, Odintsov, Igor, Smith, Roger S., Ishizawa, Kota, Liu, Allan J. W., Delasos, Lukas, Kurzatkowski, Christopher, Tai, Huichun, Gladstone, Eric, Vojnic, Morana, Kohsaka, Shinji, Suzawa, Ken, Liu, Zebing, Kunte, Siddharth, Mattar, Marissa S., Khodos, Inna, Davare, Monika A., Drilon, Alexander, Cheng, Emily, de Stanchina, Elisa, Ladanyi, Marc, Somwar, Romel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888717/
https://www.ncbi.nlm.nih.gov/pubmed/33318047
http://dx.doi.org/10.1242/dmm.047779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888717/
https://www.ncbi.nlm.nih.gov/pubmed/33318047
http://dx.doi.org/10.1242/dmm.047779

Ejemplares similares